A prospective vaccine against SarsCov2 being developed in India, that doesn’t need to be stored in refrigerators or a cold-chain storage, generated a significant number of antibodies in mouse trials against prevalent variants of the virus, according to a study in the peer-reviewed journal Viruses.
The ‘warm’ vaccine developed by the Bengaluru-based Mynvax laboratories, a company incubated at the Indian Institute of Science Bangalore, is unique among existing vaccines in that it can be stored at 37 degree Celsius for four weeks and at 100 degree Celsius for upto 90 minutes.
Most other vaccines require to be stored in refrigerators and can be kept at room temperature for no more than a few hours.
